abobotulinumtoxinA
Dicyclomine may increase the anticholinergic activities of Botulinum Toxin Type A.
Aclidinium
Dicyclomine may increase the anticholinergic activities of Aclidinium.
Alfentanil
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Alfentanil.
Advertisement
Alphaprodine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Alphaprodine.
Ambenonium
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Ambenonium.
Atracurium
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Atracurium.
Advertisement
Atracurium Besylate
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Atracurium besylate.
Atropine
The risk or severity of adverse effects can be increased when Atropine is combined with Dicyclomine.
Benactyzine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Benactyzine.
Advertisement
Bendroflumethiazide
The serum concentration of Bendroflumethiazide can be increased when it is combined with Dicyclomine.
Benzthiazide
The serum concentration of Benzthiazide can be increased when it is combined with Dicyclomine.
Benztropine
The risk or severity of adverse effects can be increased when Benzatropine is combined with Dicyclomine.
Biperiden
The risk or severity of adverse effects can be increased when Biperiden is combined with Dicyclomine.
Botulinum Toxin Type A
Dicyclomine may increase the anticholinergic activities of Botulinum Toxin Type A.
Buprenorphine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Buprenorphine.
Butorphanol
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Butorphanol.
Butylscopolamine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Butylscopolamine.
Chlorothiazide
The serum concentration of Chlorothiazide can be increased when it is combined with Dicyclomine.
Chlorphenoxamine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Chlorphenoxamine.
Chlorthalidone
The serum concentration of Chlorthalidone can be increased when it is combined with Dicyclomine.
Codeine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Codeine.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Codeine.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Codeine.
Cyclopenthiazide
The serum concentration of Cyclopenthiazide can be increased when it is combined with Dicyclomine.
Cyclopentolate
The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dicyclomine.
Darifenacin
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Darifenacin.
Demecarium
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Demecarium.
Desloratadine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Desloratadine.
Dexetimide
The risk or severity of adverse effects can be increased when Dexetimide is combined with Dicyclomine.
Dextromoramide
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Dezocine.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydrocodeine.
Diphenhydramine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Diphenhydramine.
Diphenoxylate
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Diphenoxylate.
Dipivefrin
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Dipivefrin.
Distigmine
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Distigmine.
Donepezil
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Donepezil.
Echothiophate
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Echothiophate.
Edrophonium
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Edrophonium.
Eluxadoline
Dicyclomine may increase the constipating activities of Eluxadoline.
Ethylmorphine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Ethylmorphine.
Fentanyl
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Fentanyl.
Fesoterodine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Fesoterodine.
Flavoxate
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Flavoxate.
Flavoxate Hydrochloride
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Flavoxate.
Galantamine
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Galantamine.
Gallamine Triethiodide
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Gallamine Triethiodide.
Ginkgo biloba extract
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Ginkgo biloba.
Glucagon
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Glucagon recombinant.
glucagon (rDNA)
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Glucagon recombinant.
Glycopyrronium
Dicyclomine may increase the anticholinergic activities of Glycopyrronium.
Heroin
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Heroin.
Homatropine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Homatropine.
Human Secretin
The therapeutic efficacy of Human secretin can be decreased when used in combination with Dicyclomine.
Hydrochlorothiazide
The serum concentration of Hydrochlorothiazide can be increased when it is combined with Dicyclomine.
Hydrocodone
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydrocodone.
HYDROCODONE POLISTIREX
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydrocodone.
Hydroflumethiazide
The serum concentration of Hydroflumethiazide can be increased when it is combined with Dicyclomine.
Hydromorphone
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydromorphone.
Hyoscyamine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Hyoscyamine.
incobotulinumtoxinA
Dicyclomine may increase the anticholinergic activities of Botulinum Toxin Type A.
Indapamide
The serum concentration of Indapamide can be increased when it is combined with Dicyclomine.
Ipratropium
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dicyclomine.
Ipratropium Bromide
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dicyclomine.
Ipratropium Bromide Anhydrous
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dicyclomine.
Ipratropium cation
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dicyclomine.
Isoflurophate
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Isoflurophate.
Levomethadyl
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Levomethadyl Acetate.
Levorphanol
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Levorphanol.
Malathion
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Malathion.
Mecamylamine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Mecamylamine.
Mefloquine
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Mefloquine.
Memantine
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Memantine.
Meperidine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Pethidine.
Methadone
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Methadone.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Methadyl Acetate.
Methantheline
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Methantheline.
Methixene
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Metixene.
Methscopolamine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Methscopolamine.
Methscopolamine Bromide
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Methylscopolamine bromide.
Methyclothiazide
The serum concentration of Methyclothiazide can be increased when it is combined with Dicyclomine.
Metoclopramide
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Metoclopramide.
Metolazone
The serum concentration of Metolazone can be increased when it is combined with Dicyclomine.
Mianserin
Mianserin may increase the anticholinergic activities of Dicyclomine.
Minaprine
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Minaprine.
Mirabegron
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Mirabegron.
Morphine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Morphine.
Nabilone
Dicyclomine may increase the tachycardic activities of Nabilone.
Nalbuphine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Nalbuphine.
Neostigmine
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Neostigmine.
Normethadone
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Normethadone.
O-PHENANTHROLINE
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with 1,10-Phenanthroline.
Octotropine Methylbromide
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Anisotropine Methylbromide.
Octylonium
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Otilonium.
onabotulinumtoxinA
Dicyclomine may increase the anticholinergic activities of Botulinum Toxin Type A.
Opium
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Opium.
Orphenadrine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Orphenadrine.
Oxitropium
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxitropium.
Oxybutynin
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxybutynin.
Oxycodone
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxycodone.
Oxymorphone
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxymorphone.
Oxyphenonium
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxyphenonium.
Pancuronium
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Pancuronium.
Pancuronium Bromide
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Pancuronium.
Paregoric
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Morphine.
Pentazocine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Pentazocine.
Physostigmine
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Physostigmine.
Pipecuronium
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Pipecuronium.
Pirenzepine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Pirenzepine.
Pirinitramide
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Piritramide.
Polythiazide
The serum concentration of Polythiazide can be increased when it is combined with Dicyclomine.
Potassium Chloride
Dicyclomine may increase the ulcerogenic activities of Potassium Chloride.
Pramlintide
Pramlintide may increase the anticholinergic activities of Dicyclomine.
Procyclidine
The risk or severity of adverse effects can be increased when Procyclidine is combined with Dicyclomine.
Profenamine
The risk or severity of adverse effects can be increased when Ethopropazine is combined with Dicyclomine.
Propantheline
The risk or severity of adverse effects can be increased when Propantheline is combined with Dicyclomine.
Propantheline Bromide
The risk or severity of adverse effects can be increased when Propantheline is combined with Dicyclomine.
Propiverine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Propiverine.
Propoxyphene
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Dextropropoxyphene.
Pyridostigmine
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Pyridostigmine.
Pyridostigmine Bromide
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Pyridostigmine.
Quinethazone
The serum concentration of Quinethazone can be increased when it is combined with Dicyclomine.
Quinidine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Quinidine.
Remifentanil
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Remifentanil.
rimabotulinumtoxinB
Dicyclomine may increase the anticholinergic activities of Botulinum Toxin Type B.
Rivastigmine
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Rivastigmine.
Scopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Dicyclomine.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Dicyclomine.
Secretin
The therapeutic efficacy of Secretin can be decreased when used in combination with Dicyclomine.
Solifenacin
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Solifenacin.
Sufentanil
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Sufentanil.
Sulpiride
Dicyclomine may increase the anticholinergic activities of Sulpiride.
Tacrine
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Tacrine.
Tapentadol
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Tapentadol.
Tetrahydrocannabinol
Dicyclomine may increase the tachycardic activities of Dronabinol.
Tiotropium
Dicyclomine may increase the anticholinergic activities of Tiotropium.
Tolterodine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Tolterodine.
Topiramate
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Topiramate.
Tramadol
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Tramadol.
Trichlormethiazide
The serum concentration of Trichlormethiazide can be increased when it is combined with Dicyclomine.
Trihexyphenidyl
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dicyclomine.
Trihexyphenidyl Hydrochloride
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dicyclomine.
Trimethaphan
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Trimethaphan.
Tropicamide
The risk or severity of adverse effects can be increased when Tropicamide is combined with Dicyclomine.
Trospium
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Trospium.
Tubocurarine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Tubocurarine.
Tyrothricin
The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Tyrothricin.
Umeclidinium
Dicyclomine may increase the anticholinergic activities of Umeclidinium.
Vecuronium
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Vecuronium.
